Product News and Recalls

FDA Announces Yaz/Yasmin Increase the Risk of Blood Clots by up to 75%

Large study shows “significantly higher risk” compared with “low-estrogen” pills

The FDA announced today that it has published a large retrospective study showing that women on birth control pills that contain drospirenone, an ingredient in Yaz, Yasmin, Ocella, and Beyaz, are approximately 75% more likely to have a blood clot than women on safer, established birth control pills.

Combined with the Danish study announced in the New York Times this week, there are now approximately 6 studies in recent years suggesting a higher risk of blood clots for birth control pills that contain drospirenone.

If you suffered a blood clot, pulmonary embolism, or stroke, while on Yaz, contact us to discuss your options for pursuing compensation, or have your questions answered by a qualified attorney, with no obligation. Lopez McHugh currently has a bellwether case being prepared for trial–it may be one of the first in the nation to be tried in the Yaz litigation.

Yaz contains a compound created by Bayer called drospirenone, a synthetic progestogen that may elevate the levels of potassium in the body. Side effects include heart attack, stroke, pulmonary embolism, blood clots, and even death.